We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

HepaRegeniX GmbH Secures Series B Financing to Advance First Drug Candidate to the Clinic


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "HepaRegeniX GmbH Secures Series B Financing to Advance First Drug Candidate to the Clinic"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

HepaRegeniX, a preclinical stage
company developing a novel therapy for the treatment of acute and chronic liver
diseases, has announced the closing of its Series B financing round in excess of
€11 Mio. with contribution from all its existing investors.

The proceeds will be used to advance the
first MKK4 inhibitor for the treatment of acute and chronic liver diseases to the
clinics later in 2020. MKK4 (Mitogen-Activated Protein (MAP) Kinase 4) is a key
regulator of liver regeneration and suppression of MKK4 unlocks the
regenerative capacity of hepatocytes even in severely diseased livers. Over the
last 2.5 years, HepaRegeniX focused on discovery of new and proprietary MKK4
inhibitors which led to the identification of several preclinical drug
candidates. Results from experimental, clinically relevant disease models
further validated the concept that MKK4-inhibition improves the regeneration
capacity of hepatocytes in affected organs and provided strong evidence for
successful clinical development.

Advertisement